Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions

Cell, Год журнала: 2022, Номер 185(20), С. 3789 - 3806.e17

Опубликована: Сен. 1, 2022

Cancer-microbe associations have been explored for centuries, but cancer-associated fungi rarely examined. Here, we comprehensively characterize the cancer mycobiome within 17,401 patient tissue, blood, and plasma samples across 35 types in four independent cohorts. We report fungal DNA cells at low abundances many major human cancers, with differences community compositions that differ among types, even when accounting technical background. Fungal histological staining of tissue microarrays supported intratumoral presence frequent spatial association macrophages. Comparing communities matched bacteriomes immunomes revealed co-occurring bi-domain ecologies, often permissive, rather than competitive, microenvironments distinct immune responses. Clinically focused assessments suggested prognostic diagnostic capacities mycobiomes, stage I synergistic predictive performance bacteriomes.

Язык: Английский

---

The future of early cancer detection

Nature Medicine, Год журнала: 2022, Номер 28(4), С. 666 - 677

Опубликована: Апрель 1, 2022

Язык: Английский

---

Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma

Nature Reviews Gastroenterology & Hepatology, Год журнала: 2022, Номер 19(10), С. 670 - 681

Опубликована: Июнь 8, 2022

Язык: Английский

---

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease

Cancer Discovery, Год журнала: 2021, Номер 11(12), С. 2968 - 2986

Опубликована: Ноя. 16, 2021

Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest ctDNA MRD could identify candidates adjuvant therapy and measure response to such treatment. Importantly, factors as assay type, amount of release, technical biological background can affect results. Furthermore, the clinical utility personalization remains be fully established. Here, we review supporting value in cancers highlight key considerations application this potentially transformative biomarker.

Язык: Английский

---

Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine

Nature Medicine, Год журнала: 2023, Номер 29(10), С. 2438 - 2457

Опубликована: Окт. 1, 2023

Язык: Английский

---

Biomarkers for immunotherapy of hepatocellular carcinoma

Nature Reviews Clinical Oncology, Год журнала: 2023, Номер 20(11), С. 780 - 798

Опубликована: Сен. 19, 2023

Язык: Английский

---

A clinician’s handbook for using ctDNA throughout the patient journey

Molecular Cancer, Год журнала: 2022, Номер 21(1)

Опубликована: Март 21, 2022

The promise of precision cancer medicine presently centers around the genomic sequence a patient's tumor being translated into timely, actionable information to inform clinical care. analysis cell-free DNA from liquid biopsy, which contains circulating (ctDNA) in patients with cancer, has proven be amenable various settings oncology. However, open questions surrounding validity and utility plasma-based analyses have hindered widespread adoption.Owing rapid evolution field, studies supporting use ctDNA as biomarker throughout journey accumulated last few years, warranting review latest status for clinicians who may employ their oncology programs. In this work, we take step back intricate coverage detection approaches described extensively elsewhere cover basic concepts practical implementation next generation sequencing (NGS)-guided biopsy. We compare relevant targeted untargeted plasma analysis, describe evidence utility, highlight value genome-wide particularly it relates early strategies discovery applications harnessing non-coding genome.The maturation biopsy application will require interdisciplinary efforts address current challenges. alike greatly benefit future its incorporation routine

Язык: Английский

---

Liquid biopsy in gliomas: A RANO review and proposals for clinical applications

Neuro-Oncology, Год журнала: 2022, Номер 24(6), С. 855 - 871

Опубликована: Янв. 5, 2022

There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring.The RANO (Response Assessment Neuro-Oncology) group developed a multidisciplinary international Task Force to review English on biopsy gliomas focusing most frequently used techniques, that circulating tumor DNA, cells, extracellular vesicles blood CSF.ctDNA has higher sensitivity capacity represent spatial temporal heterogeneity comparison cells. Exosomes have advantages cross intact blood-brain barrier carry also RNA, miRNA, proteins. Several clinical applications are suggested: establish when tissue not available, monitor residual disease after surgery, distinguish progression from pseudoprogression, predict outcome.There need standardization biofluid collection, choice analyte, detection strategies along with rigorous testing future trials validate findings enable entry into practice.

Язык: Английский

---

Integrated Urinalysis Devices Based on Interface‐Engineered Field‐Effect Transistor Biosensors Incorporated With Electronic Circuits

Advanced Materials, Год журнала: 2022, Номер 34(36)

Опубликована: Июль 19, 2022

Urinalysis is attractive in non-invasive early diagnosis of bladder cancer compared with clinical gold standard cystoscopy. However, the trace tumor biomarkers urine and particularly complex environment pose significant challenges for urinalysis. Here, a clinically adoptable urinalysis device that integrates molecular-specificity indium gallium zinc oxide field-effect transistor (IGZO FET) biosensor arrays, control panel, an internet terminal directly analyzing five bladder-tumor-associated proteins samples, reported classification. The IGZO FET biosensors engineered sensing interfaces provide high sensitivity selectivity identification environment. Integrating machine-learning algorithm, this can identify accuracy 95.0% cohort 197 patients 75 non-bladder individuals, distinguishing stages overall 90.0% assessing recurrence after surgical treatment. defines robust technology remote healthcare personalized medicine.

Язык: Английский

---

Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies

Science, Год журнала: 2024, Номер 383(6680)

Опубликована: Янв. 18, 2024

Liquid biopsies enable early detection and monitoring of diseases such as cancer, but their sensitivity remains limited by the scarcity analytes cell-free DNA (cfDNA) in blood. Improvements to have primarily relied on enhancing sequencing technology ex vivo. We sought transiently augment level circulating tumor (ctDNA) a blood draw attenuating its clearance report two intravenous priming agents given 1 2 hours before recover more ctDNA. Our consist nanoparticles that act cells responsible for cfDNA DNA-binding antibodies protect cfDNA. In tumor-bearing mice, they greatly increase recovery ctDNA improve detecting small tumors.

Язык: Английский

---